Medtronic reported a 3% increase in revenue to $7.8 billion, with organic revenue growth of 2%. GAAP diluted EPS increased by 169% to $0.97, while non-GAAP diluted EPS increased by 29% to $1.32. The company is reiterating its full year EPS guidance.
Revenue increased 3% reported and 2% organic.
GAAP diluted EPS of $0.97; non-GAAP diluted EPS of $1.32.
Company continued to launch new products and win share.
Market procedure volumes were impacted by COVID-19 resurgence.
The company now expects fiscal year 2022 revenue growth of 7-8% on an organic basis versus the prior expectation of approximately 9%. The company reiterated its fiscal year 2022 diluted non-GAAP EPS guidance range of $5.65 to $5.75.
Visualization of income flow from segment revenue to net income